From: Epidemiological features of hypertension among ischemic survivors in Northeast China: insights from a population-based study, 2017–2019
n
Percentages (%)
Control (n, %)
Monotherapy*
454
83.2
51 (11.2)
TDs
19
4.2
6 (31.6)
CCBs
215
47.4
21 (9.8)
BBs
5
1.1
1 (20.0)
ACEIs
28
6.2
2 (7.1)
ARBs
42
9.3
4 (9.5)
Other
145
31.9
17 (11.7)
Combination therapy
92
16.8
9 (9.8)